Clinical Trials

The purpose of this study is to evaluate the effects of A3309 on gastric, intestinal and colon transit in patients who have functional constipation.

The purpose of this study is to determine the effect of NGM282 on colonic transit, bile acid homeostasis, and fecal fat in subjects with functional constipation and in healthy individuals.

The purpose of this study is to investigate the effectiveness of virtual reality (VR) for the treatment of functional dyspepsia (FD). 

To understand the utility of measuring stomach emptying, symptoms during a stomach emptying, and blood markers of body metabolism.

The purpose of this study is to evaluate the most applicable endpoints for evaluation of the Biomerica InFoods® IBS product.

The purpose of this study is to evaluate abdominal pain response to BOS-589 in participants with diarrhea-predominant Irritable Bowel Syndrome (IBS-D) after 4 weeks of treatment, and to evaluate the overall safety and tolerability of BOS-589 in the treatment of IBS-D during 4 weeks of treatment, relative to placebo (PBO).

The aim of this study is to the number of individuals following a gluten-free diet and possible reasons including symptoms of non-celiac gluten sensitivity and functional gastrointestinal diseases (FGIDs). lso assess Diagnoses and lab values associated with celiac disease, NCGS, and FGIDs will also be assessed, as well as past GI survey data and medical record data available through the Rochester Epidemiology Project.

The purpose of this study is to:

1. To evaluate the pharmacogenomic profile (PGx) by genotyping 22 genes, including the CYP2D6 genotype, in patients with functional GI disorders.
2. To assess the impact of PGx testing on prescriber patterns in this practice.
3. To explore the impact of PGx testing on patient outcomes after an assessment in this practice.

The primary purpose of this study is to prospectively assess symptoms of bloating (severity, prevalence) in patients with diabetic gastroparesis.